CA3163157A1 - Compositions having thioredoxin activity and related methods - Google Patents

Compositions having thioredoxin activity and related methods Download PDF

Info

Publication number
CA3163157A1
CA3163157A1 CA3163157A CA3163157A CA3163157A1 CA 3163157 A1 CA3163157 A1 CA 3163157A1 CA 3163157 A CA3163157 A CA 3163157A CA 3163157 A CA3163157 A CA 3163157A CA 3163157 A1 CA3163157 A1 CA 3163157A1
Authority
CA
Canada
Prior art keywords
protein
thioredoxin
composition
peptide
active site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3163157A
Other languages
English (en)
French (fr)
Inventor
Peter B. Heifetz
Haim Moskowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ORPRO THERAPEUTICS Inc
Original Assignee
ORPRO THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ORPRO THERAPEUTICS Inc filed Critical ORPRO THERAPEUTICS Inc
Publication of CA3163157A1 publication Critical patent/CA3163157A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
CA3163157A 2020-01-03 2021-01-04 Compositions having thioredoxin activity and related methods Pending CA3163157A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062956994P 2020-01-03 2020-01-03
US62/956,994 2020-01-03
PCT/US2021/012109 WO2021138682A1 (en) 2020-01-03 2021-01-04 Compositions having thioredoxin activity and related methods

Publications (1)

Publication Number Publication Date
CA3163157A1 true CA3163157A1 (en) 2021-07-08

Family

ID=76687128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3163157A Pending CA3163157A1 (en) 2020-01-03 2021-01-04 Compositions having thioredoxin activity and related methods

Country Status (6)

Country Link
US (1) US20230071765A1 (https=)
EP (1) EP4084867A4 (https=)
JP (2) JP2023509462A (https=)
CN (1) CN115315292A (https=)
CA (1) CA3163157A1 (https=)
WO (1) WO2021138682A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168290B2 (en) 2013-03-15 2015-10-27 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization
AU2021298391A1 (en) * 2020-06-23 2023-02-02 Panasonic Intellectual Property Management Co., Ltd. Method of inactivating allergen and allergen inactivation device
EP4553160A1 (en) * 2022-07-05 2025-05-14 Tohoku University Antiviral agent, pharmaceutical composition for treating or preventing viral infection, kit for evaluating risk of viral infection becoming severe, and method for evaluating risk of viral infection becoming severe

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3515336C2 (de) * 1985-04-27 1994-01-20 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von â-Interferon
JPH10191977A (ja) * 1997-01-14 1998-07-28 Oriental Yeast Co Ltd チオレドキシン改変体及び該改変体を含むａｐ−１の転写活性能を増強する因子
JP4758525B2 (ja) * 1998-03-20 2011-08-31 武田薬品工業株式会社 生理活性ポリペプチドの徐放性製剤およびその製造法
US20060148057A1 (en) * 2002-08-02 2006-07-06 Wang Min Thioredoxin mutants and uses thereof
US20090075871A2 (en) * 2003-03-31 2009-03-19 National Institute Of Advanced Industrial Science And Technology Modified Thioredoxin
US20090203586A1 (en) * 2004-06-11 2009-08-13 Syngenta Limited Method for ameliorating an inflammatory skin condition
AU2012255132B2 (en) * 2011-05-17 2017-05-25 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
US9168290B2 (en) * 2013-03-15 2015-10-27 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization
US20210213134A1 (en) * 2018-05-17 2021-07-15 Orpro Therapeutics, Inc. Thiol-based multivalent drug delivery compositions

Also Published As

Publication number Publication date
JP2023509462A (ja) 2023-03-08
CN115315292A (zh) 2022-11-08
US20230071765A1 (en) 2023-03-09
JP2025182217A (ja) 2025-12-12
WO2021138682A1 (en) 2021-07-08
EP4084867A4 (en) 2024-01-24
EP4084867A1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
US20260027189A1 (en) Product and process for mucus viscosity normalization
US8735343B2 (en) Product and process for liquefaction of mucus or sputum
JP2025182217A (ja) チオレドキシン活性を有する組成物および関連方法
US20130172235A1 (en) Oral treatment of inflammatory bowel disease
CA2620123C (en) Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis
HK40081004A (en) Compositions having thioredoxin activity and related methods
CN108434439B (zh) 钙网蛋白的医药用途
HK1220354B (en) Product and process for mucus viscosity normalization
NZ711983B2 (en) Product and process for mucus viscosity normalization
HK40060818A (en) Pharmaceutical composition comprising insulin and triple agonist having activity with respect to all of glucagon and glp-1 and gip receptor

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241231

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241231

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241231

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250102

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250102

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250102

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250523